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hyperoxic embryonic lung growth retardation via
a FLK1-neuropilin-1-PKC dependent pathway
Americo E Esquibies1*, Anil Karihaloo2, Susan E Quaggin3, Alia Bazzy-Asaad1 and Lloyd G Cantley2Abstract
Background: Previous work in our laboratory demonstrated that hyperoxia suppressed the expression of vascular
endothelial growth factor (VEGF) by the embryonic lung, leading to increased epithelial cell apoptosis and failure of
explant airway growth and branching that was rescued by the addition of Vegf165. The aims of this study were to
determine protective pathways by which VEGF isoforms attenuate hyperoxic lung growth retardation and to
identify the target cell for VEGF action.
Methods: Timed pregnant CD-1 or fetal liver kinase (FLK1)-eGFP lung explants cultured in 3% or 50% oxygen were
treated ± Vegf121, VEGF164/Vegf165 or VEGF188 in the presence or absence of anti-rat neuropilin-1 (NRP1) antibody
or GO6983 (protein kinase C (PKC) pan-inhibitor) and lung growth and branching quantified. Immunofluorescence
studies were performed to determine apoptosis index and location of FLK1 phosphorylation and western blot studies
of lung explants were performed to define the signaling pathways that mediate the protective effects of VEGF.
Results: Heparin-binding VEGF isoforms (VEGF164/Vegf165 and VEGF188) but not Vegf121 selectively reduced
epithelial apoptosis and partially rescued lung bud branching and growth. These protective effects required
NRP1-dependent FLK1 activation in endothelial cells. Analysis of downstream signaling pathways demonstrated
that the VEGF-mediated anti-apoptotic effects were dependent on PKC activation.
Conclusions: Vegf165 activates FLK1-NRP1 signaling in endothelial cells, leading to a PKC-dependent paracrine
signal that in turn inhibits epithelial cell apoptosis.
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Low oxygen tension is a persistent feature of embryonic
life and is believed to stimulate lung development via
transcriptional upregulation of hypoxia inducible factor
dependent pathways such as Vascular endothelial growth
factor A (VEGF-A) and its receptors FMS-like tyrosine
kinase (FLT1 or VEGFR-1) and fetal liver kinase (FLK1
or VEGFR-2). VEGF-A is a well-characterized endothelial
growth factor that is secreted by several cell types includ-
ing airway epithelium and is essential for vasculogenesis
and angiogenesis [1]. Both FLT1 and FLK1 have been lo-
calized to endothelial cells and are expressed throughout* Correspondence: americo.esquibies@yale.edu
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reproduction in any medium, provided the ordevelopment. Interestingly, recent studies have shown that
VEGF-A can also play a role in epithelial cell morphogen-
esis in both the lung and the kidney, either via an indirect
effect of VEGF-stimulated vascular development on adja-
cent epithelial structures or a direct effect of VEGF-A on
the epithelial cells themselves [2,3].
Vegf-A undergoes alternative splicing in humans to
yield three major isoforms, Vegf121, 165, and 189, corre-
sponding to the mouse isoforms VEGF120, 164, and 188
[4]. VEGF120/Vegf121 is diffusible, whereas VEGF164/
Vegf165 and VEGF188/Vegf189 are variably sequestered
by binding to heparan sulfate moieties on the cell sur-
face and in the extracellular matrix. These isoforms are
expressed in distinct temporo-spatial patterns, suggesting
that each may serve a specific developmental function. In
the mouse, VEGF164 is the most abundant during earlyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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both VEGF164 and VEGF120 decrease as development
progresses, and remain relatively low in the adult lung. In
contrast, VEGF188 becomes the predominant isoform
after E16, remaining high throughout adulthood [5].
In prior work, we have shown that exposure of embry-
onic murine lung explants to hyperoxia results in down-
regulation of the RNA for all three major Vegf isoforms
with an increase in airway epithelial apoptosis and marked
reduction in lung bud branching and growth that is par-
tially rescued by the addition of recombinant human
Vegf165 [6]. This suggests that exogenous administration
of VEGF might act therapeutically to protect against hyper-
oxic lung growth retardation. Both Vegf121 and Vegf165
have been tested clinically as single agents in gene therapy
trials for human diseases [7-9]. However, it has become
evident that the VEGF-A splice variants are not biologically
equivalent or redundant [10]. For example, mice that
produce VEGF120 but not VEGF164 or 188 demonstrate
pruned vasculature and delayed airway development, dem-
onstrating that VEGF164 and/or VEGF188 are required for
normal airway maturation [11]. This differential function
of the VEGF isoforms is in part related to their distinct
downstream signaling pathways. VEGF164 and 188 utilize
both the classic VEGF receptors FLT1 and FLK1, as well
as the co-receptors neuropilin-1 (NRP1) and, in some
cases, NRP2. These co-receptors can increase the affinity
of VEGF for FLK1 and increase the downstream signaling
that mediates both the mitogenic and angiogenic re-
sponses in endothelial cells [12,13]. In contrast, VEGF120/
Vegf121 interacts with FLT1 and FLK1 but not NRP1,
while the related protein, placental growth factor (PlGF),
interacts only with FLT1 [14].
Based on these observations, we hypothesized that hep-
arin binding VEGF isoforms might initiate specific signal-
ing pathways and bind receptors in specific target cells in
order to attenuate hyperoxic lung growth retardation. To
test this hypothesis, we used either recombinant protein
or adenovirus encoding 2 main lung-expressed VEGF iso-
forms to test the effects of re-expression of individual
isoforms during hyperoxia explant culture on embryonic
mouse lung growth and branching, complemented by im-
munofluorescence and western analysis to define the cells
responding to VEGF and the downstream signaling path-
ways responsible for the protective effects.
We have found that both VEGF164/Vegf165 and
VEGF188 can rescue lung growth under hyperoxic con-
ditions, whereas Vegf121 cannot. Using a FLK1-eGFP
transgenic mouse we show that the heparin binding VEGF
isoforms activate FLK1 on developing lung endothelial cells
in a NRP1 dependent manner, leading to protein kinase C
(PKC) activation that mediates a paracrine signal to sup-
press hyperoxia-induced apoptosis in nearby airway epithe-
lial cells. These results highlight the cross-talk betweenendothelial and epithelial cells during lung development as
well as stress responses, and suggest that VEGF signaling
via a FLK1-NRP1-PKC pathway may play an important
role in prevention of hyperoxic lung growth retardation.
Methods
Lung explant culture
Timed pregnant CD-1 (Charles River) or FLK1-eGFP mice
(Samuel Lunenfeld Research Institute, Canada) were eu-
thanized on E10.5 or E11.5 (presence of vaginal plug was
considered embryonic day 0.5) and lung buds with intact
tracheas were cultured on Transwell permeable supports
with DMEM+ Penicillin 12.5 U/ml/Streptomycin 12.5 μg/
ml (Gibco) ±10% fetal bovine serum in the bottom well. In
a similar approach, we performed some experiments with
E15.5 post caval lobes with tracheas instead of whole lungs
since accurate quantitation of lung explants at this stage is
too difficult. Explants were cultured for up to 72 hours at
37°C in sealed chambers (Billups-Rothenberg, CA) equili-
brated to a humidified atmosphere of 5% CO2 with a de-
fined oxygen concentration, balanced by nitrogen. Culture
medium was replaced every 24 hours. In some experi-
ments, human Vegf165 (R&D Systems), human Vegf121
(R&D Systems), anti-rat NRP1 antibody (R&D Systems) or
GO6983 (PKC pan inhibitor, EMD Chemicals, NJ, USA)
were added to the culture medium at concentrations of
50–100 ng/ml, 50 ng/ml, 10 micrograms/ml and 1–5
microM respectively as previously described [3,6,15,16].
All animal experiments were conducted under approved
Institutional Animal Care and Use Committee guidelines
at Yale University.
Use of FLK1-eGFP mice
FLK1-eGFP mice expressing GFP under control of the
FLK1 promoter were generated by Dr. J. Rossant (Samuel
Lunenfeld Research Institute, Toronto, Ontario, Canada)
and Dr M. Ema [17,18]. FLK1-eGFP mice express GFP
selectively in mesodermal progenitors including hema-
topoietic, endothelial, cardiac and skeletal muscle pre-
cursors [17], with endothelial cells expressing eGFP
beginning at the primitive streak stage (personal com-
munication, S.E.Q.). Our immunofluorescence studies
in explanted E11 (not shown)-15.5 FLK1-eGFP lungs
demonstrated that all GFP + cells colocalized with the
endothelial marker CD31 (Pecam-1) (Additional file 1:
Figure S1).
Quantification of lung branching
Explants were randomly assigned to 3% oxygen (to mimic
in vivo lung oxygenation) or 50% oxygen culture (a con-
centration that we have previously shown to cause inhib-
ition of VEGF expression accompanied by suppression of
explant growth [6]) with or without added recombinant
Vegf165, recombinant Vegf121, anti-rat NRP1 antibody or
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plants with an adenovirus encoding either DsRed (con-
trol), VEGF164 or VEGF188 for 2 days in 3% oxygen,
followed by exposure to 50% oxygen. Lungs were photo-
graphed at 0, 24, 48 and 72 hours (after initiation of
hyperoxia). The images were utilized to determine the
number of terminal bud branches (structures with blind
ends) and to quantitate total branch length (sum of
straight lines beginning at the point of branching and end-
ing at the branch tip). Each experiment utilized 9–10
explanted lungs with 2–3 lungs in each experimental
group which were averaged and counted as an n of 1, and
was repeated on at least 3 occasions.
Cell apoptosis assay
Analysis of apoptosis was performed using TUNEL In Situ
Cell Death Detection Kit (Roche) and cleaved caspase 3
(Asp175) antibody (Alexa Fluor 488 or 594) (1:100, Cell
Signaling). Sections were counterstained with DAPI. A
minimum of 12 views of 3–4 airway structures were ana-
lyzed for each explant and at least 3 explants were ana-
lyzed per experiment (averaged to comprise an n of 1 for
each experiment) with a total of 5 experiments per condi-
tion. Cells were included only if they were contained
within the airway branch and were defined as apoptotic
only if the entire nucleus was stained by TUNEL or cyto-
plasm was stained by cleaved caspase 3 antibody. Over
2000 cells were counted for each condition. The total
apoptosis index was defined as the percentage of TUNEL
or cleaved caspase 3 positive cells/total number of cells in
the airway structure (DAPI stained nuclei). Other apop-
tosis indices were a) endothelial compartment: total num-
ber of functional GFP positive expression and TUNEL
positive cells/total number of GFP positive, b) non endo-
thelial (mesenchymal and epithelial) compartment: total
number of GFP negative TUNEL positive cells/total GFP
negative DAPI positive cells or c) epithelial compartment:
total number of TUNEL positive or cleaved caspase 3
positive cells within the epithelial compartment (identified
by cytokeratin staining)/Total cytokeratin positive cells.
Adenoviral infection of embryonic lung explants
Lung explants were harvested from E10.5 mouse em-
bryos and cultured under 3% oxygen for 6 hours in 10%
fetal bovine serum and Penicillin 12.5 U/ml/Streptomycin
12.5 μg/ml (Gibco) to allow for adhesion to the Transwell
permeable supports. Explants were then starved and in-
fected with 150 adenoviral particles per cell (an E10.5
mouse lung explant has approximately 15,000 cells by our
count) of either Ad-Vegf164, Ad-Vegf188; or Ad-DsRed (a
kind gift from Dr. Frank Giordano. Yale University [10]) for
2 days to allow for protein expression. Subsequently, ex-
plants were cultured in oxygen levels of 3% or 50% for an-
other 2 days. Lungs were imaged using Hoffman contrastand fluorescence microscopy. VEGF isoform expression
was quantified by real time PCR normalized to Glyceralde-
hyde 3-phosphate Dehydrogenase (GAPDH) expression
and reported as 2-dCt. The primers were: Vegf-A164 Re-
verse: 5′-GAACAAGGCTCACAGTGATTTTCT-3′, Vegf-
A164 and Vegf-A 188 Forward: 5′-TGCAGGCTGCTG-
TAACGATG-3′, Vegf-A188 Reverse: 5′- CTCCAGGATT
TAAACCGGGATT-3′, Gapdh Forward: 5′-TCACCAC-
CA TGGAGAAGGC-3′, Gapdh Reverse: 5′-GCTAAGCA
GTTGGTGGTGCA-3′
Immunoblotting
At least twelve lung explants/condition at E11.5 or post
caval lobes at E15.5 were cultured in 3% and 50% oxygen
for 2 days followed by homogenization in RIPA buffer
(1% Triton X-100, 1% deoxycholate, 0.1% SDS, 20 mM
Tris, 0.16 M NaCl, 1 mM EGTA, 1 mM EDTA, 15 mM
sodium fluoride, 1 mM phenylmethylsulfonyl fluoride,
0.5 μg/mL leupeptin), and 0.5 μg/mL pepstatin A con-
taining Proteinase Inhibitor Complete and phosphatase
inhibitor (Roche Molecular Biochemicals, IN). Lysates
were centrifuged at 10,000 rpm for 30 minutes at 4°C
and supernatants used as whole tissue lysates. Protein
concentration was measured using the Bradford assay.
Equal amounts of protein (50–70 micrograms) were
separated on NuPAGE 4-12% Bis–Tris Gels and trans-
ferred to nitrocellulose, as described earlier. Western
blots were performed with antibodies against p-FLK1
(Tyr 996)(1:200 Santa Cruz Biotechnology, CA), phospho-
PKC (1:1000 Cell Signaling Technologies), p-Akt 1/2/3
(1:500, Santa Cruz Biotechnology, CA) and phospho-p44/
42 MAPK (Erk ½) (1:1000 Cell Signaling Technologies).
To ensure equal loading, membranes were re-probed with
and antibody to PKC, Akt and Actin (I-19) (1:2000 Santa
Cruz Biotechnology, CA). Specific bands were visualized
after incubation with the respective secondary anti-
bodies by autoradiography by using Enhanced Chemi-
luminescence Substrate (Western Lightning Plus-ECL,
PerkinElmer Inc, MA).
Densitometry measurements
Densitometry measurements of Western blots from each
experimental group were obtained (n = 5 for each group),
and absolute values were normalized to actin.
Immunostaining analysis
Lung explants were pooled and placed in tissue freezing
medium and cut in semi-thin serial frozen sections (0.8-
1 μm). Sections were washed in PBS followed by antigen re-
trieval (heating to 90°C for 3–10 minutes). Lungs were
washed × 3 in PBS and non-specific binding blocked by
incubation in 10% goat serum, 0.1% bovine serum albumin
(BSA) and PBS for 1 hour. Sections were incubated over-
night at 4°C with mouse anti-keratin pan monoclonal
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(p-FLK1) (Tyr 1175) (1:200 Cell Signaling), cleaved caspase
3 (Asp 175) antibody (Alexa Fluor 488 or 594) (1:100 Cell
Signaling) or purified rat anti mouse CD31 (Pecam BD
Pharmingen 1:50) in 10% goat serum, 0.1% BSA and PBS
solution, then washed × 3 and incubated with goat anti-
mouse antibody, biotinylated goat anti-rabbit antibody or
goat anti rat conjugated to Alexa 594 (1:200). Airway ana-
lysis was similar to Methods for Cell apoptosis assay. Cells
were included only if they were contained within the airway
branch and were defined as positive if the entire membrane
was stained by p-FLK1. Over 2000 cells were counted for
each condition. The Total p-FLK1 index was defined as the
percentage of p-FLK1-positive cells/total number of cells in
the airway structure and the p-FLK1 endothelial index was
defined as the percentage of p-FLK1-positive, GFP positive
cells/total number of GFP positive cells.
Statistical analysis
All data are expressed as means ± SD. Paired Student’s t
test or one-tailed Student’s t test were used for calculat-
ing statistical significance, where appropriate. A p < 0.05
was considered statistically significant.
Results
Heparin-binding VEGF isoforms partially rescue lung
growth in hyperoxic explant culture
We have previously shown that all VEGF isoforms are
downregulated and lung development severely impairedFigure 1 Ad-Vegf188 rescues hyperoxia suppression of Vegf188 mRNA
explanted embryonic lung. (A) E12.5 explanted lung infected with adenovi
Photographs at 10x magnification. a: airway, m: mesenchyme. B’) E10.5 lun
adenovirus or Ad-Vegf188 and then exposed at E12 to either 3% or 50% ox
used as control. n = 4, *p <0.05 vs. 3% alone and 50% oxygen + AdVegf188following explant exposure to 50% oxygen. Since VEGF188
is the predominantly expressed VEGF isoform in the devel-
oping lung, we compared the ability of VEGF188 and
VEGF164 to rescue lung explants from hyperoxic injury
using an adenoviral expression system [10]. Infection with
a control adenovirus expressing intracellular Ds-Red re-
vealed that transgene expression is most prominent in the
mesenchymal cells surrounding the developing airways
(Figure 1A’). Titration of the Ad-Vegf188 dose to 150 viral
particles/cell led to restoration of Vegf188 mRNA expres-
sion in explants cultured in 50% oxygen to the level seen
following culture in 3% oxygen (Figure 1B’). Similar expres-
sion levels of mRNA for Vegf164 were found following in-
fection with this titer of Ad-Vegf164 (data not shown). This
pattern of expression was predicted to restore local levels
of the relevant VEGF isoform at a location that would be
available to both the mesenchymal and epithelial cell com-
partments. Of note, there was no detectable effect of con-
trol adenoviral infection on airway branching or branch
length at 48 hours after explant culture.
Explants harvested from E10.5 mouse embryos were
then infected with either Ad-Vegf164, Ad-Vegf188 or
Ad-DsRed control, and cultured at 37°C in a sealed
chamber with 3% oxygen for 2 days (to allow for protein
expression), followed by culture in either 3% or 50% oxy-
gen for another 2 days. As previously described, expos-
ure of lung explants infected with control adenovirus to
50% oxygen resulted in a marked decrease in airway
branch numbers and branch length as compared to thoseexpression. A’) Adenoviral control infection (Ad-DsRed) in mouse
rus (Hoffmann image). (B) Same lung under immunofluorescence.
g explants were harvested, infected with either Ad-DsRed control
ygen for 2 d. Quantitative PCR of Vegf188 was performed with Gapdh
at E12 + 2.
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fection with either Ad-Vegf188 or Ad-Vegf164 followed by
culture in 50% oxygen partially rescued the decrease in
branch numbers and total branch length (Figure 2C,D),
comparable to the rescue that we previously observed
with recombinant Vegf165 [6].Vegf121 fails to rescue explant lung growth under
hyperoxic culture
In addition to the heparin-binding VEGF isoforms 164
and 188, non-heparin binding VEGF120 is also expressed
in the developing lung and suppressed by hyperoxic cul-
ture. To test the ability of this isoform to rescue lung bud
growth under hyperoxic conditions, explants from E11.5
mouse embryos were harvested and cultured in: a) 3%
oxygen alone, b) 50% oxygen alone, c) 50% oxygen + re-
combinant human Vegf165 (50 ng/ml daily), or d) 50%
oxygen + recombinant human Vegf121 (50 ng/ml daily)
at 37°C in a sealed chamber for 2 days. Total number of
lung bud branches and total branch length were quanti-
tated. Similar to the results with Ad-Vegf164, treatment
with Vegf165 partially rescued lung bud branching and
growth under hyperoxic conditions, whereas recombin-
ant Vegf121 failed to rescue either lung bud branching
or elongation (Figure 3). Cumulatively, these data dem-
onstrate that the two heparin binding VEGF isoforms
are equally capable of rescuing lung growth during hyper-
oxic explant culture, whereas VEGF120/Vegf121 appears
to be insufficient to confer protection.Figure 2 Hyperoxia-dependent inhibition of lung morphogenesis is a
harvested, infected with Ad-DsRed (A,B), Ad-Vegf164 (C), or Ad-Vegf188 (D)
(E) Total number of terminal branches and (F) total branch length were qu
vs. 3% alone and **p <0.05 vs. 50% oxygen + DsRed at E12 + 2. PhotographVegf165 activates FLK1 on explant GFP + endothelial cells
in a neuropilin-dependent fashion
Neuropilin-1 (NRP1) serves as a VEGF co-receptor that
enhances VEGF164/Vegf165 and VEGF188/Vegf189 sig-
naling via VEGF2 (FLK1), whereas VEGF120/Vegf121
does not utilize NRP1 for signaling. To determine which
cells in the lung explant are responding to heparin-
binding VEGF isoforms, and whether that response is
dependent on NRP1, lung explants were isolated from
FLK1-eGFP mice that express GFP in CD31+ endothelial
progenitor cells (Additional file 1: Figure S1, [18]). FLK1-
eGFP E11.5 lung explants were cultured for 2 days in ei-
ther 3% or 50% oxygen ± recombinant Vegf165 with either
anti-NRP1 or isotype control, followed by fixation and im-
munostaining for phospho-FLK1 and detection of GFP by
fluorescence microscopy. Explants cultured in 3% oxygen
without exogenous Vegf165 demonstrated pFLK1 staining
selectively in GFP + cells (Figure 4A, quantified in E,F).
Explants exposed to 50% oxygen demonstrated a marked
reduction in pFLK1 staining (Figure 4B), consistent with
the reduction in VEGF expression in those lungs [6]. The
addition of exogenous Vegf165 partially rescued FLK1 ac-
tivation in GFP + cells of explants cultured in 50% oxygen,
whereas Vegf165 failed to activate FLK1 in the presence of
the NRP1 blocking antibody (Figure 4C, D, quantified in
E, F). These data demonstrate that VEGF predominantly
activates FLK1 on GFP + endothelial cells, and that this
activation requires NRP1.
To determine the importance of NRP1-FLK1 activation
in the phenotypic response to VEGF during hyperoxia,ttenuated by VEGF164 and VEGF188. E10.5 lung explants were
and then exposed at E13 to either 3% (A) or 50% (B-D) oxygen for 2 d.
antitated in explants treated as above. n =4 for each group, *p <0.05
s at 4x magnification. Bar = 1 mm.
Figure 3 Hyperoxia-dependent inhibition of lung morphogenesis is attenuated by Vegf165 but not Vegf121. E11.5 lung explants
exposed to (A) 3% oxygen (B) 50% oxygen (C) 50% oxygen + Vegf165 (50 ng/mL) or (D) 50% oxygen + Vegf121 (50 ng/mL ) for 2 d. (E) total
number of terminal branches and (F) total branch length from lungs cultured as above were quantitated at E11.5 + 2. n = 4 per group, *p <0.05
vs. 3% alone and **p <0.05 vs. 50% alone and ***p <0.05 vs. 50% + Vegf165 at E11.5 + 2. Photographs at 4x magnification. Bar = 1 mm.
Figure 4 Vegf165 activates FLK1 on GFP + endothelial cells in a NRP1-dependent manner. FLK1-eGFP E11.5 + 2 lung explants were exposed
to either 3% (A) or 50% (B-D) oxygen in the presence of either anti-NRP1 antibody (D, 10 microgram/ml) or isotype control (B) for 30 minutes,
followed by Vegf165 (C,D, 100 ng/ml) for 15 min. Explants were immunostained for phosphorylated FLK1 (pFLK1). Arrows indicate pFLK1 positive
(red), GFP positive (green) endothelial cells. E) Quantitation of pFLK1 positive cells/total cells x 100 and F) Quantitation of pFLK1 positive, GFP
positive cells/total GFP positive cells x 100 respectively. n = 4 separate experiments with 2–3 lungs/condition/experiment. *p <0.05 vs. 50% +
Isotype and 50% + Anti-NRP1 + Vegf165. **p <0.05 vs. 50% + Isotype and 50% + Anti-NRP1 + Vegf165. Photographs at 40x magnification. Bar = 20
microns. White asterisks show airway lumen.
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recombinant Vegf165 with either anti-NRP1 antibody or
isotype control. Quantification of total terminal branches
and total branch length in these experiments revealed that
inhibition of FLK1 activation via the neutralizing antibody
to NRP1 completely blocked the protective effect of re-
combinant Vegf165 addition to explant growth in the set-
ting of hyperoxia (Figure 5A-D, quantified in E, F).
Heparin-binding VEGF isoforms prevent
hyperoxia-induced apoptosis in airway epithelial cells
The functional role of NRP1-FLK1 activation in VEGF-
mediated protection from hyperoxic lung injury was an-
alyzed using TUNEL staining of FLK1-eGFP explants
cultured for 2 days under 3% oxygen, 50% oxygen, 50%
oxygen + Vegf165 or 50% oxygen + anti-NRP1 + Vegf165.
Quantitation of total TUNEL positive cells/DAPI-posi-
tive nuclei demonstrated that Vegf165 decreased the
number of apoptotic cells in hyperoxia treated explants,
and that this protective effect was prevented by the
NRP1 blocking antibody (Figure 6A-D, quantified in E).Figure 5 Vegf165 attenuation of lung growth retardation requires NR
conditions and total number of terminal branches and total branch length
Vegf165 (C) 50% oxygen + isotype control antibody for 30 minutes and the
(anti-NRP1, 10 microgram/ml) for 30 minutes and then 100 ng/ml of Vegf1
from lungs cultured as above. n = 4, *p <0.05 compared to 50% oxygen +The overall increase in apoptosis seen following hyper-
oxic explant culture is predominantly due to an increase
in the GFP negative cells (non-endothelial cell compart-
ment). These cells did not have detectable FLK1 activa-
tion in response to Vegf165 (Figure 4), yet comprised
the majority of cells that exhibited the Vegf165/NRP1-
dependent reduction in apoptosis (quantified in 6 F).
Interestingly, endothelial cells (defined as GFP positive
cells outside of the airway basement membrane) exhib-
ited a VEGF independent decrease in apoptosis when ex-
posed to hyperoxia that was not significantly affected by
the addition of Vegf165 (Figure 7A’). These cells made
up less than 10% of all explant cells (Figure 7B’) and thus
did not significantly impact the overall apoptotic rate.
Since VEGF188 also provided morphologic protection to
explants cultured under hyperoxic conditions (Figure 2),
lungs treated with either Ad-Vegf188 or Ad-Vegf164 were
analyzed for cellular apoptotic rates in the different cellular
compartments. Analysis of TUNEL staining (Figure 8A’)
and cleaved caspase-3 staining (Figure 8B’) combined
with cytokeratin staining to identify airway epithelialP1. E11.5 + 2 lung explants were cultured for 2 d. under the indicated
quantitated. (A) 50% oxygen alone (B) 50% oxygen + 100 ng/ml of
n 100 ng/ml of Vegf165 (D) 50% oxygen + anti neuropilin-1 antibody
65 (E) total number of terminal branches and (F) total branch length
Vegf165. Photographs at 4× magnification. Bar = 1 mm.
Figure 6 Vegf165 attenuated hyperoxia-induced apoptosis in non-endothelial cells. FLK1-eGFP E11.5 lungs were harvested and exposed
for 2 d. to (A) 3% oxygen, (B) 50% oxygen + isotype control, (C) 50% oxygen + Vegf165 (100 ng/ml) and (D) 50% oxygen + anti-NRP1 (10
microgram/ml) + Vegf165 (100 ng/ml), followed by staining for TUNEL (red) and DAPI (blue). Endothelial cells fluoresce green (GFP). Arrows
indicate TUNEL positive cells. (E) Quantitation of TUNEL positive cells/total cells x 100 and (F) TUNEL positive, GFP negative cells/total GFP
negative cells × 100. n = 4 separate experiments with 2–3 lungs/condition/experiment. *p <0.05 vs. 50% and 50% + Anti-NRP1 + Vegf165. Bar = 20
microns. Photographs at 40× magnification. White asterisks point airway lumen.
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tosis predominantly in epithelial cells of lung explants
(Figures 8A’A,B and 8B’A,B quantified in 8A’E,F and 8B’E,F).
Infection with either Ad-Vegf188 or Ad-Vegf164 reduced
epithelial apoptosis to rates that were indistinguishable
from that seen in control explants. These data demon-
strate that culture of explants in 50% oxygen suppresses
the expression of heparin-binding VEGF isoforms that
normally serve to activate endothelial cell NRP1-FLK1
and suppress apoptosis of nearby epithelial cells. The
addition of VEGF164/Vegf165 or VEGF188 during hyper-
oxic culture can rescue endothelial FLK1 activation and
prevent epithelial cell apoptosis.Figure 7 Hyperoxia suppresses endothelial cell apoptosis. FLK1-eGFP E
(B) 50% oxygen + Isotype, (C) 50% oxygen + Vegf165 (100 ng/ml). (A’) Qua
***p <0.05 vs. 50% + Isotype and 50% + Vegf165. (B’) Total number of GFP
counted for this experiment in thousands during exposure to 3% oxygen.VEGF 165 attenuation of hyperoxic injury requires
endothelial PKC pathway activation
Multiple laboratories have shown that activation of the
ERK1/2, PI 3-K, and PKC pathways are required for
tubulogenesis and/or branching morphogenesis in epi-
thelial cells stimulated by growth factors such as HGF,
epidermal growth factor and VEGF [3,19]. To determine
what NRP1-dependent signaling pathway(s) mediate the
protective effects of Vegf165, E11.5 (Figure 9A-D) and
E15.5 (Figure 9E-F) lung explants were cultured under
50% oxygen and stimulated with Vegf165 for 15 min ±
anti-NRP1. Western analysis showed that explants treated
with Vegf165 had a 4-fold increase in the phosphorylation11.5 lungs were harvested and exposed for 2 d. to (A) 3% oxygen,
ntitation of TUNEL positive, GFP positive cells/total GFP positive cells.
positive (endothelial) cells and GFP negative (non-endothelial) cells
Figure 8 VEGF164 and VEGF188 decrease hyperoxia-induced apoptosis in airway epithelial cells. (A’) E10.5 lungs were harvested, infected
with Ad-DsRed (A,B), Ad-Vegf164 (C) or Ad-Vegf188 (D) and exposed on E12.5 to either 3% (A) or 50% (B-D) oxygen for 2 d. followed by TUNEL
staining (green), cytokeratin staining (red), and DAPI staining (blue). The cytokeratin positive epithelial compartment is outlined with white dots.
Arrows indicate TUNEL positive nuclei (green). (E) Quantification of TUNEL positive cells/total cells and F) TUNEL positive, cytokeratin positive
cells/total cytokeratin positive cells. (B’) Explant lungs treated as in (A’) with similar conditions (A-D) were stained with anti-cleaved caspase 3
(green), cytokeratin (red) and DAPI (blue). Arrows indicate cleaved caspase 3 positive cells. (E) Quantification of cleaved caspase 3 positive cells/
total cells and F) Cleaved caspase 3 positive, cytokeratin positive cells/total cytokeratin positive cells. n = 4 separate experiments with 2–3 lungs/
condition/experiment. *p < 0.05 3% oxygen + DsRed, 50% oxygen + Ad-Vegf164 or Ad-Vegf188 vs. 50% oxygen + Ad-DsRed, n = 4 Bar = 20 microns.
Photographs at 100× magnification.
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Figure 9 Neuropilin-1 is required for Vegf165 activation of PKC and AKT signaling. Lysates of E11.5 + 2 (A-D) and E15.5 + 2 (E-F) lung
explants exposed to 50% oxygen ± isotype control ± anti-NRP1 (10 micrograms/ml) ± Vegf165 (100 ng/ml, 15 minutes) were western blotted for
pFLK1, phospho-ERK (pERK), phospho-AKT (pAKT), AKT, pan-phospho-PKC (pPKC) and PKC with actin as loading control. Representative immunoblots
are shown in (A, B, C, D, E and F). Accompanying graph of n =4 experiments. *p <0.05 50% oxygen + Vegf165 vs. 50% + isotype (for pFLK1 and pPKC)
and 50% oxygen + anti-NRP1 and then Vegf165 (for pFLK1, pAKT and pPKC).
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in the presence of the NRP1 blocking antibody (Figure 9A).
Analysis of downstream signaling pathways demonstrated
that VEGF-stimulated activation of PKC and Akt were
NRP1-dependent, and thus candidates for inducing the
Vegf-stimulated protective response, whereas activation of
ERK was NRP1 independent (Figure 9B-F).
Based on our observation that Vegf165/NRP1-dependent
PKC activation was more pronounced than was Akt activa-
tion, we chose to focus on the role of PKC signaling in the
protection of lung explants from hyperoxic injury. Whole
lung explants from E11.5 and post caval lobes from E15.5
mouse embryos were harvested and cultured in 3% or 50%
oxygen ± Vegf165 ± the pan-PKC inhibitor GO6983. Treat-
ment with GO6983 did not alter basal explant growth/
branching under 3% oxygen, but prevented the Vegf165-
mediated rescue of growth under 50% oxygen culture at
both time points (Figure 10A’, B’). Consistent with our
finding that the Vegf165-dependent rescue of explant
branching and growth correlated with increased epithelialcell survival under hyperoxic conditions, the addition of
GO6983 prevented the Vegf165-dependent decrease in
hyperoxia-induced epithelial apoptosis as judged by both
TUNEL (Figure 11A-B for explants at E11.5) and cleaved
caspase 3 staining (Figure 11C-D for explants at E11.5 and
11E-F for post caval lobes at E15.5).Discussion
The airway is central to the defense of the lung against en-
vironmental toxins such as high oxygen concentrations or
infectious pathogens. During lung development the airway
epithelium is a major source of the vasculogenic factor
VEGF that is believed to be critical in synchronizing the
parallel development of the pulmonary vasculature and
the airways [1,20]. Here we extend the scope of that
epithelial-endothelial cross-talk by demonstrating that
suppression of VEGF expression following exposure to
hyperoxia leads to the loss of endothelial FLK1-NRP1 acti-
vation and increased epithelial apoptosis.
Figure 10 Vegf165 requires PKC activation to maintain explant growth under hyperoxia. A’. E11.5 whole lung explants were exposed to
3% ± GO6983 (5 μM) (A-B) and 50% oxygen (C) for 3 days in the presence of Vegf165 (100 ng/ml, D), Vegf165 + DMSO (E), Vegf165 + GO6983
(5 μM, F) followed by quantification of total number of terminal branches (G) and total branch length (H). n =5 separate experiments. *p <0.05
vs. C, D, E and F. **p <0.05 vs. C and F at E11.5 + 3. Bar = 1 mm. Photographs at 4x magnification. B’ E15.5 lung post caval lobe explants (B’ A-F)
were exposed to 3% ± GO6983 (5 μM) (A-B) and 50% oxygen (C) for 2 days in the presence of Vegf165 (100 ng/ml, D), Vegf165 + DMSO (E),
Vegf165 + GO6983 (5 μM, F) followed by quantification of total number of terminal branches (G) and total branch length (H). n =4 separate
experiments. *p <0.05 vs. C and F. **p <0.05 vs. C and F at E15.5 + 2. Bar = 0.5 mm. Photographs at 4× magnification.
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developing lung, the heparin sulfate binding isoforms
predominate with Vegf164 expressed during early em-
bryogenesis and Vegf188 dominating after E16 [6]. Based
on the phospho-FLK1 staining that we observed in
control and VEGF stimulated FLK1-eGFP transgenic ex-
plants, it appears that the major target of VEGF is the
endothelial cell. Furthermore, we show that functional
activation of endothelial FLK1 by VEGF requires the en-
gagement of the NRP1 co-receptor. Consistent with this,
we find that only the VEGF isoforms that utilize NRP1
for maximal FLK1 activation (164/165 and 188/189) are
able to confer functional protection against hyperoxic
lung growth retardation.
NRP1 enhances the binding of VEGF to FLK1 and
thereby increase its tyrosine kinase activity [21,22]. The
endothelial cell response to this increased kinase activityhas been shown to include activation of several down-
stream signaling pathways including the extracellular-
signal-regulated kinases ERK1/2, phosphatidylinositol
3-kinase (PI 3-K) and its effector Akt, as well as PKC. Our
results indicate that Vegf165 stimulates FLK1 dependent
activation of all three of these intracellular pathways in the
explanted lung. This activation occurs within 15 minutes
of Vegf165 addition, suggesting that these signaling path-
ways are being activated in the phospho-FLK1 positive
endothelial cells; although we cannot exclude the possibil-
ity that such activation may occur in the airway epithe-
lium as well.
Although each of these signaling pathways has been
shown under specific conditions to activate anti-apoptotic
responses, we detected no difference in endothelial apop-
totic rates following Vegf165 addition despite a significant
increase in FLK1 activation. In fact, in contrast to the
Figure 11 Activation of PKC is required for Vegf-mediated anti-apoptotic responses. A-B. E11.5 lung explants exposed to either 3% oxygen
or 50% oxygen ± Vegf165 (100 ng/ml) ± GO6983 (5 μM) for 3 days and stained for TUNEL, cytokeratin and DAPI. (A) Quantitation of total TUNEL
positive cells/total cells x 100 in explants cultured. (B) Quantitation of total TUNEL positive, cytokeratin positive cells/total cytokeratin positive cells.
*p <0.05 vs. 50% oxygen, 50% oxygen + GO6983 and 50% oxygen + GO6983 + Vegf165 at E11.5 + 3. C-D E11.5 lung explants exposed to either 3%
oxygen or 50% oxygen ± Vegf165 (100 ng/ml) ± GO6983 (5 μM) for 3 days and stained for cleaved caspase 3, cytokeratin and DAPI. (C) Quantitation of
total cleaved caspase 3 positive cells/total cells x 100. (D) Quantitation of total cleaved caspase 3 positive, cytokeratin positive cells/total cytokeratin
positive cells. *p <0.05 vs. 50% oxygen, 50% oxygen + GO6983 and 50% oxygen + GO6983 + Vegf165 at E11.5 + 3. E-F E15.5 Post caval lung explants
exposed to either 3% oxygen or 50% oxygen ± Vegf165 (100 ng/ml) ± GO6983 (5 μM) for 2 days and stained for cleaved caspase 3, cytokeratin and
DAPI. (E) Quantitation of total cleaved caspase 3 positive cells/total cells x 100. (F) Quantitation of total cleaved caspase 3 positive, cytokeratin positive
cells/total cytokeratin positive cells. *p <0.05 vs. 50% oxygen, 50% oxygen + GO6983 and 50% oxygen + GO6983 + Vegf165 at E15.5 + 2 .n = 3–4 separate
experiments with 2–3 lungs/ condition/experiment.
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hyperoxic culture, endothelial apoptosis was significantly
decreased in explants exposed to hyperoxia. A similar
finding made by Reyburn et al. determined that thinning
of the distal airways during hyperoxia was halted in the
setting of hyperoxia due to failure of apoptosis of mesen-
chymal cells [23]. Thus the suppression of VEGF expres-
sion and subsequent loss of endothelial FLK1 activation
seen during hyperoxic culture ([6] and Figure 4) does not
appear to induce endothelial apoptosis.
These findings suggest that the mechanism of VEGF-
dependent protection against epithelial apoptosis is not dueto improved endothelial cell survival, but rather a FLK1-
stimulated endothelial-epithelial paracrine response. Our
demonstration that the Vegf165-stimulated ERK1/2 activa-
tion was not dependent on NRP1 activation, whereas the
Vegf165-mediated anti-apoptotic response was dependent
on NRP1 activation, led us to exclude this pathway as a
likely mediator of the paracrine protective response. Instead
we focused the current studies on PKC since activation of
this pathway exhibited the greatest dependence of FLK1-
NRP1 co-stimulation.
PKCs are serine threonine kinases that are abundantly
expressed during lung development. Studies done using
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have revealed that these enzymes regulate multiple cellular
responses including vascular permeability, smooth muscle
contraction, cell migration, cell proliferation and apoptosis
[24,25]. There is increasing evidence that VEGF-mediated
activation of PKC can also induce protection against
damaging insults (e.g. radiation, inflammatory diseases,
hyperoxia) [16,26-28]. Our phospho-PKC antibody de-
tected two PKC species that were activated in response
to Vegf165, migrating at ranges between 80 and 90 kDa,
respectively (Figure 9C-E). The higher molecular-weight
band is of the predicted size of PKC ε, which has been
shown to be a Vegf-Flk1 activation target in human
endothelial cells [29]. The 80-kDa band could be one of
several PKCs, including PKC α, βI, βII, γ, η, and/or θ.
VEGF has been found to activate many of these iso-
forms in endothelial cells, including PKC α, βI, βII, and
γ [30-32].
Our observation that non-endothelial cells are more
protected by the VEGF-FLK2/NRP1-PKC pathway than
are endothelial cells may involve activation of antioxi-
dant defense enzymes. It has been suggested that in the
premature newborn, failure to elevate the activities of
these antioxidant enzymes can increase the lung damage
caused by hyperoxia [33]. Peroxiredoxins belong to an
antioxidant protein family with many distinct members
(I-VI), with some members highly expressed in bron-
chial/alveolar epithelial cells [34]. Interestingly, Das et al.
found that hyperoxia-mediated induction of peroxiredoxin
expression in A549 cells is partially dependent on PKC
signaling [35]. VEGF/PKC-dependent elevation of peroxir-
edoxin in the airway epithelium may therefore provide a
pathway for protection against oxidative stress during ex-
posure to higher levels of oxygen.
The identity of the VEGF-FLK1/NRP1-PKC-dependent
paracrine signal is of great interest but as yet unknown.
Matrix metalloproteinases (MMPs) are one attractive
candidate. In endothelial progenitor cells VEGF can
stimulate MMP secretion [36], and the secretion of
many MMPs, including MMP1, MMP2, MMP3 and
MMP9 has been found to be regulated by PKC activa-
tion [37,38]. MMPs can act to release matrix- and cell-
associated growth factors such as FGF2, VEGF that can
in turn stimulate anti-apoptotic effects by binding their
cognate receptors on nearby cells [39,40]. Elucidation of
the role of MMPs in the current endothelial-epithelial
cross-talk clearly requires additional studies.
While this study has identified a novel VEGF-stimulated
FLK1-NRP1 mediated mechanism of endothelial-epithelial
cross-talk, there are limitations to the approach utilized
that must be considered when placing this data in the lar-
ger context of in vivo exposure to hyperoxia. By definition,
explants lack a normal circulation and all of the regulatory
signals that would be derived from that circulation. Forexample, the expression of MMPs can be markedly altered
in response to the inflammation that is seen following
in vivo exposure to hyperoxia [41]. Furthermore, in order
to accurately quantify morphologic responses to hyperoxia
we utilized embryonic mouse lungs from E11.5 and lung
lobe segments from E15.5, quite early in development as
compared to most pre-term infants. The experiments at
E15.5 were within the range of the canalicular stage of
human lung development (17–25 weeks of gestation) and
recapitulated the findings in E11.5 explants. However, we
cannot rule-out a shift in the dependence on VEGF-
NRP1-FLK1 signaling closer to birth. Finally, we cannot
exclude the importance of the fibroblast-epithelial cross
talk during branching morphogenesis since hyperoxia can
induce apoptosis of the mouse lung mesenchyme in the
canalicular stage [42].
Conclusions
We propose that VEGF heparin binding isoforms nor-
mally activate FLK1-NRP1 in the hypoxic developing
lung endothelium, leading to PKC activation that in-
duces a paracrine signal to suppress epithelial apoptosis.
This pathway is downregulated in hyperoxia due to sup-
pression of VEGF164 and 188 expression. The ability of
exogenously added Vegf165 to restore FLK1-NRP1-PKC
activation and suppress epithelial apoptosis suggests that
this pathway may provide a novel approach to decrease
hyperoxic lung growth retardation. In particular, since
excessive VEGF administration can induce vascular leak
[43] and disrupt airway development, these data suggest
that a selective activator of the specific PKC isoform in-
volved in stimulating the paracrine signal and/or
addition of the paracrine factor itself might serve as less
toxic therapies.
Additional file
Additional file 1: Figure S1. CD31 endothelial marker colocalizes with
FLK-eGFP cells. A-I. E15.5 Flk1-GFP lung explants are seen under fluores-
cence microscopy (green) (A,D and G). CD31 (red) endothelial marker is
observed in B, E and H. Colocalization of GFP cells and CD31 is observed
in C, F and I. Photographs at 20×, 40× and 100× magnification.
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